Light

your way.

Get the full picture with trusted tumor immune response results from our in-house validated antibodies.

Bethyl Laboratories is dedicated to improving lives by supporting scientific discovery through its qualified polyclonal and recombinant rabbit monoclonal antibody products and ELISA kits. Our portfolio consists of over 9,500 catalog products; more than 8,200 primary antibodies targeting over 3,300 proteins and 1,300 secondary antibodies raised against immunoglobulins from over 25 species. Since 1972, every antibody we sell has been manufactured and validated on-site in the USA to exacting standards. Our newest catalog offering of recombinant rabbit monoclonal antibodies serves to advance immuno-oncology research.

At Bethyl, we put a lot in every drop.

Advancing Immuno-Oncology Research

Immuno-oncology has moved from an emerging field to one of the cornerstones of cancer therapy. Unlike traditional therapies such as radiation or chemotherapy which target the tumor itself, immunotherapy stimulates the patients own immune system to target and eradicate cancerous cells. In order to attack cancerous cells, the immune system must be able to respond in several ways. First, antigen presenting cells (APC) such as macrophages and dendritic cells must process tumor associated antigens (TAA) derived from dying cancer cells and display them on their surface via MHC-II receptors. Second, antigen presenting cells must generate a protective T-cell population. Last, cancer-specific, CD8+ cytotoxic T-cells must evade immunosuppressive (checkpoints) signals being expressed in the tumor.

As different immunotherapies have become available as treatment options, it is clear that not every patient responds. Thus, profiling the tumor microenvironment to determine the type of immune cells present and expression of immunosuppressive signals within the tumor is a key component of designing new therapies and predicting responsive patients.

The current clinical data suggests that profiling the tumor microenvironment to determine the type of immune cells present and expression of immunosuppressive signals within the tumor is a key component of designing new therapies and predicting responsive patients. Bethyl maintains an extensive catalog of antibodies that can be used to identify immune cell type, tumor cells, and the presence of checkpoint inhibitors.

Successful inhibition of the PD-1 and CTLA-4 signaling systems have revolutionized treatment options.

Early immunotherapy ideas involved using vaccines to present tumor associated antigens to APCs. Recently, the most exciting therapies have involved clearing the immunosuppressive signals within the tumor using checkpoint inhibitors. Successful inhibition of the PD-1 and CTLA-4 signaling systems have revolutionized treatment options. The identification of other receptor systems such as Tim-3, Lag-3, and OX40 which down regulate T-cells has expanded possibility of new checkpoint inhibitors.

Download our Immune Checkpoints in Cancer Therapy supplement

Detection of CD45 in a FFPE section of human small intestine by IHC. Antibody: Rabbit anti-CD45 recombinant monoclonal antibody [BL-178-12C7] (A700-012). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Detection: DAB.

Detection of human PD-L1 (red) and Lamin-A/C (green) in FFPE lung carcinoma by IHC-IF. Antibody: Rabbit anti-PD-L1 recombinant monoclonal [BLR020E] (A700-020) and rabbit anti-Lamin-A/C (A303-430A). Secondary: DyLight® 594-conjugated goat anti-rabbit IgG (A120-201D4) and DyLight® 488-conjugated goat anti-rabbit IgG (A120-201D2). Counterstain: DAPI (blue).

Detection of human CD247/CD3Z in FFPE metastatic lymph node from lung carcinoma by IHC. Antibody: Rabbit anti-CD247/CD3Z recombinant monoclonal [BL-336-1B2] (A700-017). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.

Competitor Comparisons

Each assay was performed in accordance to the manufacturer’s recommend protocol as outlined in each product’s datasheet.

Competitor’s Rabbit anti-PD-L1 Monoclonal Antibody
 

Application: IHC
Sample: Lung carcinoma

Bethyl’s Rabbit anti-PD-L1 Recombinant Monoclonal Antibody
[BLR020E] A700-020-1

Application: IHC
Sample: Lung carcinoma

Competitor A’s Rabbit anti-PD-L1 Monoclonal Antibody
 

Application: IHC
Sample: Tonsil

Competitor B’s Rabbit anti-PD-L1 Monoclonal Antibody
 

Application: IHC
Sample: Tonsil

Bethyl’s Rabbit anti-PD-L1 Recombinant Monoclonal Antibody
[BLR020E] A700-020-1

Application: IHC
Sample: Tonsil

Competitor’s Rabbit anti-CD3E Monoclonal Antibody
 

Application: IHC
Sample: Tonsil

Bethyl’s Rabbit anti-CD3E Recombinant Monoclonal Antibody
[BL-298-5D12] A700-016-1

Application: IHC
Sample: Tonsil

Tumor Infiltrating Lymphocytes Poster

Click to Enlarge

Antibodies for Immuno-Oncology Research:

Immune Cells and Tumor Microenvironment

The tumor microenvironment contains normal cells, tumor cells, lymphocytes, and blood vessels. The identification and interaction of these tumor microenvironment constituents aids in diagnostics, treatment and response measures.

Immune Cell Type Markers:

Pan-immune cells:
CD45
A700-012 & A300-376A

CD3/CD3E
A304-291

T-cell:
CD3/CD3E
A700-016

CD247/CD3Z
A700-017

B-cell:
CD20
A500-017A

 

Macrophage:
CD68
A500-018A

HLA-DR
A500-022A

Natural Killer Cells:
CD7
A304-396A

CD117/c-Kit
A303-252A

General APC cells:
CD54/ICAM-1
A302-873A & A302-874A

Tumor Cell Markers:

Proliferation:
Ki-67
A700-021, IHC-00375 & IHC-00395

PCNA
A300-276A, A300-276B, A300-277A, A300-277B & IHC-00012

Epithelial:
Cytokeratin
A500-019A

Mesenchymal:
Vimentin
A301-620A & IHC-00314

Angiogenesis:
CD31
IHC-00055

T-Cell Markers

The ability of the immune system to respond to cancer is dependent on T-cells specific for tumor-associated antigens. Both immune related cells and tumor cells can influence the activation state of T-cells. The ability to phenotype activation status and sub-categories of T-cells present in the tumor microenvironment is important for predicting immune response towards the tumor.

T-cell Markers:
CD3/CD3E
A700-016 & A304-291

CD247/CD3Z
A700-017

Helper T-cell:
CD4
A700-015

Cytoxic T-cell:
CD8
A500-021A

Granzyme B
A700-022

Memory T-cell:
CD45RO
A500-020A

Immune Checkpoints

Tumors suppress immune responses by activation negative signaling pathways termed immune checkpoints or co-inhibitory pathways. The ability of T-cells to mount an effective response is also dependent the presence of co-stimulatory signaling. The characterization of the repertoire of inhibitory and stimulatory molecules can help determine the type of immunotherapy which will generate the most effective patient response.

Co-inhibitory:
PD-L1
A700-020

Looking for a specific target that's not listed?

Guarantee Statement

Bethyl is dedicated to delivering the highest standards of product and service quality. Recognizing that your research and time are valuable, we promise to stand behind our products. Should one of our antibodies fail to return satisfactory results when used in the species, application and under the same conditions stated on the product datasheet, Bethyl will offer a full product replacement, credit or refund at the investigator’s discretion. Before providing product replacement, credit or refund, we ask the investigator to complete an application specific questionnaire and work with our Technical Support team to identify potential steps to optimize conditions.

Every Bethyl product ships with a 100% guarantee; choose Bethyl antibodies with confidence.